We expect that this study will provide robust experimental evidence regarding the role of LKB1 deacetylation in the treatment of NASH and suggest that tranilast may be a promising new drug for the pharmacological management of metabolic syndrome. Here, STK11 is linked to metabolic dysfunction-associated steatohepatitis.